AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05144646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL
Description: The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
Study NCT05144646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL
Description: In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
Study NCT05057975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunrise
Description: Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
Study NCT05057975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polysomnography
Description: Reference protocol to diagnose OSA (in-lab or outpatient PSG)
Study NCT05853133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
Study NCT05853133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
Study NCT05464654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 g Polynucleotide vaginal suppositories
Description: 3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
Study NCT05464654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated estrogens cream 1g Tube
Description: Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
Study NCT05605340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Description: 10 healthy, home-delivered meals per week + brief weekly remote behavioral support
Study NCT03921060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: treatment with denosumab every 6 months for up to 5 years
Study NCT06477094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratus Nimbus Electrosurgical RF Multi-Tined Expandable Electrode
Description: Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stratus Nimbus Electrode
Study NCT06477094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Venom Radiofrequency Cannula
Description: Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stryker Venom Cannula
Study NCT04757597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
Study NCT04753164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-539313
Description: ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Study NCT04753164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Study NCT05336058 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
Study NCT04966676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA blood test
Description: Blood sample will be taken for cfDNA testing
Study NCT04966676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Antineoplastic agent
Study NCT04966676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Antineoplastic agent
Study NCT04966676 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
Study NCT05163964 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle Intervention
Description: Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
Study NCT06080529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sandbag exercise
Description: Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
Study NCT06085690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence-based intervention Plan for the Prevention of CRBSI in ICU patients
Description: On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention.
Study NCT06007235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CACIPLIQ20
Description: CACIPLIQ20 contains RGTA heparan sulphate mimetics
Study NCT06007235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Saline solution in identical spray bottles
Study NCT05154526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy: High velocity-low amplitude technique
Study NCT05154526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program
Study NCT05154526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Exercise program
Study NCT05411289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area.
Study NCT05411289 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupressure
Description: Pressures were applied on sham points consecutively
Study NCT05873972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0
Study NCT05873972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0
Study NCT00863005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201
Description: Cream
Study NCT00863005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K201
Description: Cream
Study NCT00863005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201
Study NCT00863005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K201
Study NCT05727657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: 120mg subcutaneous Day 0 and Day 14
Study NCT05813704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Crossing System of Shanghai MicroPort Rhythm
Description: The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
Study NCT06440876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and Imagery
Description: See music and imagery arm description.
Study NCT05193474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated palliative care
Description: shared decision making with patient, and timely integrated palliative care according to patient's preference
Study NCT06395441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: Given PO
Study NCT06528392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
Study NCT06395441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06395441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06395441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06410755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring system using a insole-type gait analyzer
Description: The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
Study NCT04579900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy and duodenal biopsy and sampling
Description: All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
Study NCT04579900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy and duodenal biopsy and sampling
Description: All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (5mg/kg, IV)
Description: 5 mg/kg to be administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, IV)
Description: 20 mg/kg to be administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, SC)
Description: 20 mg/kg to be administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (40mg/kg, IV)
Description: 40 mg/kg to be administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (40mg/kg, SC)
Description: 40 mg/kg to be administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (1.4g, IV)
Description: 1.4gram to be administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (1.4g, SC)
Description: 1.4gram to be administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20mg/kg, IV)
Description: VRC07-523LS 20mg/kg administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20mg/kg, SC)
Description: VRC07-523LS 20mg/kg administered via SC infusion
Study NCT05237843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
Study NCT05237843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1.4g, IV)
Description: VRC07-523LS 1.4g administered via IV infusion
Study NCT04807335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT001
Description: nasal spray
Study NCT04807335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: iv single dose
Study NCT04807335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: iv single dose
Study NCT04694027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: omega 3 1000 mg
Study NCT04694027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VitaE
Description: vitamin e 400 mg
Study NCT04870125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)
Description: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
Study NCT04870125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Medical air
Description: Inhaled Medical Air for up to 90 minutes daily for 3 days.
Study NCT06324396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)
Description: A single oral dose of sildenafil will be administered to all study subjects.
Study NCT06324396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
Description: A single oral dose of pravastatin will be administered to all study subjects.
Study NCT05347706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula
Description: Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
Study NCT05248685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual CD33/CLL1 CAR T
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
Study NCT05643794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
Study NCT05433922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: cyclosporine in combination with Avatrombopag to treat
Study NCT05909384 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
Study NCT05643794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive Placebo during the dosing periods as pre-defined.
Study NCT05769205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI with contrast
Study NCT05705362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple Crossover
Description: Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
Study NCT05705362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Side branch opening
Description: According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
Study NCT05973253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prepared drop of medroxy progestrone acetat 1%
Description: In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1.4g, SC)
Description: VRC07-523LS 1.4g administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (40mg/kg, IV)
Description: VRC07-523LS 40mg/kg administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (20mg/kg, IV)
Description: PGT121.414.LS 20mg/kg administered via IV infusion